GALNT9 and prostate adenocarcinoma: Immunohistochemical (IHC) staining confirmed that both GALNT9 and O‐GalNAc were increased in clinical biospecimens from patients with NEPC compared with those from patients with PrAD (Figure S4b–d, Supporting Information).